Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: ER+ Breast Cancer
Interventions: DRUG: Entinostat|DRUG: Aromatase Inhibitor (AI) Therapy
Sponsor: Syndax Pharmaceuticals